APVO Aptevo Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—
Leverage & solvency
Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $3.11M | $12.29M |
| R&D expense | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M |
| SG&A expense | $11.77M | $10.22M | $11.77M | $13.87M | $14.70M |
| Operating income | -$26.31M | -$24.60M | -$28.88M | -$28.64M | -$21.40M |
| Pretax income | -$25.97M | -$24.13M | -$18.65M | $7.01M | -$29.41M |
| Income tax | $0 | — | — | — | — |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M |
| EBITDA | -$26.07M | -$24.25M | -$28.31M | -$27.74M | -$20.26M |
| EPS (basic) | -87.27 | -31,460.23 | -2,316.83 | 1.57 | -6.07 |
| EPS (diluted) | -87.27 | -31,460.23 | -2,316.83 | 1.57 | -6.07 |
| Weighted avg. shares (diluted) | 315,535 | 767 | 7,515 | 5.10M | 4.69M |
| Balance sheet | |||||
| Cash & equivalents | $21.62M | $8.71M | $16.90M | $22.64M | $45.04M |
| Current assets | $23.08M | $10.66M | $19.07M | $27.45M | $52.57M |
| PP&E, net | $303,000 | $543,000 | $895,000 | $1.46M | $2.38M |
| Total assets | $27.19M | $15.59M | $24.84M | $34.22M | $56.60M |
| Current liabilities | $6.05M | $6.21M | $7.22M | $8.71M | $34.76M |
| Short-term debt | — | — | — | $2.00M | $11.67M |
| Long-term debt | — | — | $0 | $1.46M | $3.71M |
| Total debt | — | — | $0 | $3.46M | $15.37M |
| Total liabilities | $9.81M | $10.84M | $12.62M | $16.24M | $55.38M |
| Shareholders' equity | $17.38M | $4.75M | $12.22M | $17.97M | $1.22M |
| Net debt | — | — | -$16.90M | -$19.18M | -$29.67M |
| Shares outstanding | 997,830 | 4,051 | 11,958 | 6.47M | 4.90M |
| Cash flow statement | |||||
| Operating cash flow | -$25.59M | -$23.79M | -$11.73M | -$21.02M | -$21.68M |
| Capital expenditure | — | — | — | $29,000 | $713,000 |
| Free cash flow | — | — | — | -$21.05M | -$22.39M |
| Investing cash flow | $0 | $0 | $0 | -$29,000 | -$713,000 |
| Financing cash flow | $38.50M | $15.60M | $6.00M | -$2.62M | $26.16M |
| Depreciation & amortization | $240,000 | $352,000 | $567,000 | $901,000 | $1.14M |
| Stock-based compensation | $96,000 | $1.07M | $2.19M | $1.80M | $1.64M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.